NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
The rights issue in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has today been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed shares (BTA) will be replaced by ordinary shares. The last day for trading with BTA is on May 25, 2020 and new shares will be transferred to the respective custodian account/VP account on May 29, 2020. After registration with the Swedish Companies Registration Office, NeuroVive’s share capital amounts to SEK 13,483,673.30 and the number of shares is 269,673,466.
Information about paid subscribed share
Ticker: NVP BTA
ISIN code: SE0014262408
Last day of trading: May 25, 2020
Erik Penser Bank AB acts as financial advisor to NeuroVive in connection with the rights issue and Cirio Advokatbyrå AB acts as legal advisor.